{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:06:28Z","timestamp":1787151988142,"version":"build-2736575974"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-018-1045-9","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T09:04:00Z","timestamp":1547802240000},"page":"109-124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Current and Emerging Treatment Strategies for Graves\u2019 Orbitopathy"],"prefix":"10.1007","volume":"79","author":[{"given":"Natalia","family":"Genere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-8125","authenticated-orcid":false,"given":"Marius N.","family":"Stan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"8","key":"1045_CR1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362(8):726\u201338.","journal-title":"N Engl J Med"},{"issue":"8","key":"1045_CR2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","volume":"93","author":"AK Eckstein","year":"2009","unstructured":"Eckstein AK, et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93(8):1052\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"3\u20134","key":"1045_CR3","first-page":"177","volume":"5","author":"FF Rundle","year":"1945","unstructured":"Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy. Clin Sci. 1945;5(3\u20134):177\u201394.","journal-title":"Clin Sci"},{"issue":"3","key":"1045_CR4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","volume":"129","author":"GB Bartley","year":"2011","unstructured":"Bartley GB. Rundle and his curve. Arch Ophthalmol. 2011;129(3):356\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1045_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, et al. The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy. Eur Thyroid J. 2016;5(1):9\u201326.","journal-title":"Eur Thyroid J"},{"key":"1045_CR6","doi-asserted-by":"crossref","first-page":"249125","DOI":"10.1155\/2015\/249125","volume":"2015","author":"J Barrio-Barrio","year":"2015","unstructured":"Barrio-Barrio J, et al. Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.","journal-title":"J Ophthalmol"},{"issue":"1","key":"1045_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, et al. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9\u201314.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1045_CR8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, et al. Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1045_CR9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, et al. Public health relevance of Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2013;98(1):145\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1045_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, et al. Psychosocial morbidity of Graves\u2019 orbitopathy. Clin Endocrinol (Oxf). 2005;63(4):395\u2013402.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1045_CR11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/bjophthalmol-2011-300487","volume":"95","author":"T Fayers","year":"2011","unstructured":"Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol. 2011;95(12):1670\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1045_CR12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, et al. Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82(7):773\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1045_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9394(14)72666-2","volume":"120","author":"GB Bartley","year":"1995","unstructured":"Bartley GB, et al. The incidence of Graves\u2019 ophthalmopathy in Olmsted County,Minnesota. Am J Ophthalmol. 1995;120(4):511\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1045_CR14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","volume":"12","author":"WM Wiersinga","year":"2002","unstructured":"Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves\u2019 ophthalmopathy. Thyroid. 2002;12(10):855\u201360.","journal-title":"Thyroid"},{"issue":"4","key":"1045_CR15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","volume":"269","author":"MF Prummel","year":"1993","unstructured":"Prummel MF, Wiersinga WM. Smoking and risk of Graves\u2019 disease. JAMA. 1993;269(4):479\u201382.","journal-title":"JAMA"},{"issue":"12","key":"1045_CR16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1136\/bjophthalmol-2014-306463","volume":"99","author":"L Xing","year":"2015","unstructured":"Xing L, et al. Smoking was associated with poor response to intravenous steroids therapy in Graves\u2019 ophthalmopathy. Br J Ophthalmol. 2015;99(12):1686\u201391.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1045_CR17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein A, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol. 2003;87(6):773\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1045_CR18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998;129(8):632\u20135.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1045_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45(4):477\u201381.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1045_CR20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","volume":"21","author":"RS Bahn Chair","year":"2011","unstructured":"Bahn Chair RS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593\u2013646.","journal-title":"Thyroid"},{"issue":"5","key":"1045_CR21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel MF, et al. Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy. Arch Intern Med. 1990;150(5):1098\u2013101.","journal-title":"Arch Intern Med"},{"issue":"10","key":"1045_CR22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421.","journal-title":"Thyroid"},{"issue":"2","key":"1045_CR23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, et al. Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy. N Engl J Med. 1998;338(2):73\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"1045_CR24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s40618-016-0484-y","volume":"39","author":"HX Li","year":"2016","unstructured":"Li HX, et al. Relation between therapy options for Graves\u2019 disease and the course of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest. 2016;39(11):1225\u201333.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1045_CR25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/eje.0.1300494","volume":"130","author":"L Tallstedt","year":"1994","unstructured":"Tallstedt L, et al. Does early administration of thyroxine reduce the development of Graves\u2019 ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130(5):494\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1045_CR26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1089\/thy.2012.0258","volume":"23","author":"MN Stan","year":"2013","unstructured":"Stan MN, et al. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves\u2019 ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23(5):620\u20135.","journal-title":"Thyroid"},{"issue":"1","key":"1045_CR27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","volume":"42","author":"P Perros","year":"1995","unstructured":"Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995;42(1):45\u201350.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1045_CR28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bjophthalmol-2017-310695","volume":"102","author":"ABD Grisolia","year":"2018","unstructured":"Grisolia ABD, et al. Non-surgical treatment for eyelid retraction in thyroid eye disease (TED). Br J Ophthalmol. 2018;102:158\u201363.","journal-title":"Br J Ophthalmol."},{"issue":"6","key":"1045_CR29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0161-6420(02)01041-2","volume":"109","author":"JM Uddin","year":"2002","unstructured":"Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology. 2002;109(6):1183\u20137.","journal-title":"Ophthalmology"},{"issue":"3","key":"1045_CR30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002341-200405000-00001","volume":"20","author":"KE Morgenstern","year":"2004","unstructured":"Morgenstern KE, et al. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthalmic Plast Reconstr Surg. 2004;20(3):181\u20135.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"1045_CR31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MED.0000000000000190","volume":"22","author":"J Kohrle","year":"2015","unstructured":"Kohrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes. 2015;22(5):392\u2013401.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"20","key":"1045_CR32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, et al. Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med. 2011;364(20):1920\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"1045_CR33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000442440","volume":"5","author":"N Dehina","year":"2016","unstructured":"Dehina N, et al. Lack of association between selenium status and disease severity and activity in patients with graves\u2019 ophthalmopathy. Eur Thyroid J. 2016;5(1):57\u201364.","journal-title":"Eur Thyroid J"},{"issue":"8","key":"1045_CR34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/ceo.12317","volume":"42","author":"G Gao","year":"2014","unstructured":"Gao G, et al. Meta-analysis of methylprednisolone pulse therapy for Graves\u2019 ophthalmopathy. Clin Exp Ophthalmol. 2014;42(8):769\u201377.","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"1045_CR35","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","volume":"94","author":"H Stiebel-Kalish","year":"2009","unstructured":"Stiebel-Kalish H, et al. Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94(8):2708\u201316.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1045_CR36","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1045_CR37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","volume":"166","author":"C Marcocci","year":"2012","unstructured":"Marcocci C, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol. 2012;166(2):247\u201353.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1045_CR38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.mcna.2012.01.014","volume":"96","author":"MN Stan","year":"2012","unstructured":"Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy. Med Clin North Am. 2012;96(2):311\u201328.","journal-title":"Med Clin North Am"},{"issue":"12","key":"1045_CR39","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1045_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1507\/endocrj.EJ16-0083","volume":"64","author":"Y He","year":"2017","unstructured":"He Y, et al. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves\u2019 ophthalmopathy: a prospective, randomized controlled trial. Endocr J. 2017;64(2):141\u20139.","journal-title":"Endocr J"},{"issue":"6","key":"1045_CR41","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","volume":"99","author":"W Zhu","year":"2014","unstructured":"Zhu W, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2014;99(6):1999\u20132007.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1045_CR42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","volume":"40","author":"L Bartalena","year":"2017","unstructured":"Bartalena L, et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves\u2019 orbitopathy? J Endocrinol Invest. 2017;40(5):547\u201353.","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"1045_CR43","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","volume":"108","author":"CA Gorman","year":"2001","unstructured":"Gorman CA, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology. 2001;108(9):1523\u201334.","journal-title":"Ophthalmology"},{"issue":"1","key":"1045_CR44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel MF, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):15\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9214","key":"1045_CR45","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits MP, et al. Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet. 2000;355(9214):1505\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1045_CR46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ophtha.2007.10.028","volume":"115","author":"EA Bradley","year":"2008","unstructured":"Bradley EA, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(2):398\u2013409.","journal-title":"Ophthalmology"},{"issue":"5","key":"1045_CR47","first-page":"322","volume":"11","author":"CM Ng","year":"2005","unstructured":"Ng CM, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves\u2019 ophthalmopathy: a preliminary study. Hong Kong Med J. 2005;11(5):322\u201330.","journal-title":"Hong Kong Med J"},{"issue":"6","key":"1045_CR48","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","volume":"56","author":"L Bartalena","year":"1983","unstructured":"Bartalena L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983;56(6):1139\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1045_CR49","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF03347943","volume":"14","author":"C Marcocci","year":"1991","unstructured":"Marcocci C, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853\u201360.","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"1045_CR50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1055\/s-0043-116945","volume":"49","author":"M Oeverhaus","year":"2017","unstructured":"Oeverhaus M, et al. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves\u2019 Orbitopathy. Horm Metab Res. 2017;49(10):739\u201347.","journal-title":"Horm Metab Res"},{"issue":"2","key":"1045_CR51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1045_CR52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, et al. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1045_CR53","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M. Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy\u2014lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1045_CR54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","volume":"16","author":"G Kahaly","year":"1986","unstructured":"Kahaly G, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16(5):415\u201322.","journal-title":"Eur J Clin Invest"},{"issue":"20","key":"1045_CR55","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF, et al. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med. 1989;321(20):1353\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1045_CR56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"Ye X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247\u201355.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1045_CR57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40618-016-0441-9","volume":"39","author":"M Riedl","year":"2016","unstructured":"Riedl M, et al. Prospective, systematically recorded mycophenolate safety data in Graves\u2019 orbitopathy. J Endocrinol Invest. 2016;39(6):687\u201394.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1045_CR58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1045_CR59","first-page":"422","volume":"6","author":"E Rivera-Grana","year":"2015","unstructured":"Rivera-Grana E, et al. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015;6(2):422.","journal-title":"J Clin Exp Ophthalmol."},{"issue":"1","key":"1045_CR60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcjo.2017.07.009","volume":"53","author":"A Rubinov","year":"2018","unstructured":"Rubinov A, et al. Role of methotrexate in thyroid-related orbitopathy. Can J Ophthalmol. 2018;53(1):34\u20138.","journal-title":"Can J Ophthalmol"},{"key":"1045_CR61","doi-asserted-by":"crossref","first-page":"128903","DOI":"10.1155\/2014\/128903","volume":"2014","author":"D Strianese","year":"2014","unstructured":"Strianese D, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014:128903.","journal-title":"J Ophthalmol"},{"issue":"6","key":"1045_CR62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/cen.13834","volume":"89","author":"Z Sipkova","year":"2018","unstructured":"Sipkova Z, et al. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol (Oxf). 2018;89(6):834\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1045_CR63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1530\/acta.0.1220008","volume":"122","author":"P Perros","year":"1990","unstructured":"Perros P, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122(1):8\u201312.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"4","key":"1045_CR64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","volume":"6","author":"R Rajendram","year":"2018","unstructured":"Rajendram R, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299\u2013309.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1045_CR65","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1997.7.579","volume":"7","author":"L Baschieri","year":"1997","unstructured":"Baschieri L, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves\u2019 ophthalmopathy. Thyroid. 1997;7(4):579\u201385.","journal-title":"Thyroid"},{"issue":"2","key":"1045_CR66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","volume":"106","author":"G Kahaly","year":"1996","unstructured":"Kahaly G, et al. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy. Clin Exp Immunol. 1996;106(2):197\u2013202.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"1045_CR67","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1210\/jc.2004-0697","volume":"89","author":"AJ Dickinson","year":"2004","unstructured":"Dickinson AJ, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89(12):5910\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1045_CR68","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03344124","volume":"29","author":"TC Chang","year":"2006","unstructured":"Chang TC, Liao SL. Slow-release lanreotide in Graves\u2019 ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2006;29(5):413\u201322.","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1045_CR69","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1210\/jc.2006-1105","volume":"91","author":"MN Stan","year":"2006","unstructured":"Stan MN, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2006;91(12):4817\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1045_CR70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2004-1334","volume":"90","author":"JL Wemeau","year":"2005","unstructured":"Wemeau JL, et al. Octreotide (long-acting release formulation) treatment in patients with graves\u2019 orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005;90(2):841\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1045_CR71","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"RS Douglas","year":"2008","unstructured":"Douglas RS, et al. B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181(8):5768\u201374.","journal-title":"J Immunol"},{"issue":"6","key":"1045_CR72","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol. 2008;181(6):4397\u2013405.","journal-title":"J Immunol"},{"issue":"18","key":"1045_CR73","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748\u201361.","journal-title":"N Engl J Med"},{"issue":"9","key":"1045_CR74","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1210\/jc.2003-030380","volume":"88","author":"S Kumar","year":"2003","unstructured":"Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2003;88(9):4246\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9617","key":"1045_CR75","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987\u201397.","journal-title":"Lancet"},{"issue":"2","key":"1045_CR76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV Perez-Moreiras","year":"2014","unstructured":"Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC. Treatment of active corticosteroid-resistant graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162\u20137.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1045_CR77","first-page":"1153","volume":"77","author":"BCRV Atienza-Mateo","year":"2018","unstructured":"Atienza-Mateo BCRV, Mart\u00edn-Varillas J, et al. SAT0601 Anti-il6-receptor tocilizumab in graves\u2019 orbitopathy. multicenter study of 29 patients. Ann Rheumatic Dis. 2018;77:1153\u20134.","journal-title":"Ann Rheumatic Dis"},{"key":"1045_CR78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, et al. Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390.","journal-title":"Am J Ophthalmol."},{"issue":"12","key":"1045_CR79","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D, et al. The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study. Eye (Lond). 2005;19(12):1286\u20139.","journal-title":"Eye (Lond)"},{"issue":"5","key":"1045_CR80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","volume":"30","author":"R Ayabe","year":"2014","unstructured":"Ayabe R, et al. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(5):415\u20139.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"1045_CR81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","volume":"24","author":"OM Durrani","year":"2005","unstructured":"Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005;24(2):117\u20139.","journal-title":"Orbit"},{"key":"1045_CR82","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fimmu.2017.01460","volume":"8","author":"NAJ Dawson","year":"2017","unstructured":"Dawson NAJ, Vent-Schmidt J, Levings MK. Engineered tolerance: tailoring development, function, and antigen-specificity of regulatory T cells. Front Immunol. 2017;8:1460.","journal-title":"Front Immunol"},{"issue":"2","key":"1045_CR83","first-page":"81","volume":"46","author":"P Sanders","year":"2011","unstructured":"Sanders P, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. 2011;46(2):81\u201399.","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"1045_CR84","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","volume":"133","author":"JD Stein","year":"2015","unstructured":"Stein JD, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015;133(3):290\u20136.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1045_CR85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0950-351X(05)80333-7","volume":"6","author":"RS Bahn","year":"1992","unstructured":"Bahn RS, Bartley GB, Gorman CA. Emergency treatment of Graves\u2019 ophthalmopathy. Baillieres Clin Endocrinol Metab. 1992;6(1):95\u2013105.","journal-title":"Baillieres Clin Endocrinol Metab"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1045-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1045-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1045-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T17:44:27Z","timestamp":1606067067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1045-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1045-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"18 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"NG reports no conflicts of interest. MNS reports participating in Advisory Board meeting with Horizon Pharma, manufacturer of teprotumumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received for the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}